BALTIMORE -- Immunex Corp. on Thursday said its Leukinegranulocyte macrophage colony stimulating factor met first-quarter sales goals within the first three weeks of sales.

Company President Michael Kranda told the 16th annual Alex.Brown & Sons Health Care Seminar here that Immunex nowexpects sales for the quarter of $4.2 million. The company alsosaid it will begin Phase II/III trial of interleukin-1 forpressure ulcers late this year. Immunex (NASDAQ:IMNX) closedat $42.75 on Thursday, up $1.88.

Synergen Inc. (NASDAQ:SYGN) climbed $1.50 to $31.75 afterreporting it will begin Phase III trials of Antril interleukin-1rafor sepsis and septic shock in late 1991. The company will alsostart clinicals of Antril for inflammatory bowel disease, acuteand chronic myelogenous leukemia and asthma this year.

Quadra Logic Technologies Inc. (NASDAQ:QLT) closed at $9.50,rising $1.75 in two sessions after reporting Wednesday positivepreliminary results of Phase III trials of Photofrin fortreatment following removal of tumors caused by bladder,esophageal and lung cancers. -- Steve Usdin

(c) 1997 American Health Consultants. All rights reserved.